Single Cure Found For Three Neglected Diseases

The Leishmania parasite is one of three targeted by a new potential drug. Kateryna Kon/Shutterstock

When a single cure is offered for multiple conditions it’s usually a scam, like a snake oil salesmen who promises a single cure for all ills. However, evidence that one chemical can treat three neglected tropical diseases has been published in Nature, a much more reliable source than a fast-talking salesman on the back of a wagon or a late night infomercial.

Sleeping sickness, leishmaniasis, and Chagas disease are all parasitic diseases neglected by medical researchers because they afflict some of the poorest people on Earth. With those affected unable to afford treatments, pharmaceutical companies have shown little interest in bringing treatments to market.

Dr Frantisek Supek of the Genomics Institute of the Novartis Research Foundation has found a possible solution – a class of drugs that hit all three diseases, reducing the costs compared to the development required for three unrelated treatments.

"We found that these parasites harbor a common weakness,” Supek said in a statement. “We hope to exploit this weakness to discover and develop a single class of drugs for all three diseases."

Collectively the three diseases cause more than 50,000 deaths a year, and infect millions. Each is caused by single-celled organisms called kinetoplastids, although the species responsible are different.

Leishmaniasis is spread by sand fly bites and infects more than a million people in tropical and subtropical countries, a minority having the more serious visceral form that infects the spleen or liver.

Sleeping sickness is not a general inability to wake up, specifically referring to African trypanosomiasis, spread by the tsetse fly. Death from it is preceded by years of confusion, personality changes and slurred speech.

Chagas disease is restricted to the western hemisphere where it affects 8 million people exposed to the feces of triatomine bugs.

Full Article
Comments

If you liked this story, you'll love these

This website uses cookies

This website uses cookies to improve user experience. By continuing to use our website you consent to all cookies in accordance with our cookie policy.